Market revenue in 2023 | USD 82.6 million |
Market revenue in 2030 | USD 118.6 million |
Growth rate | 5.3% (CAGR from 2023 to 2030) |
Largest segment | Attenuated vaccine |
Fastest growing segment | DNA Vaccines |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
Key market players worldwide | Lonza Group Ltd, FUJIFILM Holdings Corp, Merck KGaA, Catalent Inc, Icon PLC, Syngene, Curia, Ajinomoto Co Inc, IDT Biologika |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
Attenuated vaccine was the largest segment with a revenue share of 30.02% in 2023. Horizon Databook has segmented the Spain vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Spain offers a high potential in the vaccine contract manufacturing market. It is considered lucrative due to its well-developed healthcare infrastructure, skilled investigators, proven research quality, high patient recruitment volumes, and robust pharmaceutical industries.
In addition, supportive government policies and a conducive regulatory environment contribute to Spain's market. This contributes to the overall expansion of the vaccine contract manufacturing market in Spain. Some of the vaccine contract manufacturing providers in Spain are Catalent, Inc.; Lonza Group; and AbbVie Contract Manufacturing.
Furthermore, the country has a rising number of ongoing clinical studies, which are expected to contribute to market growth. The growing number of innovations in clinical trials and rising demand for generics & biologics are expected to drive market growth. This trend has drawn the attention of market players, which is likely to contribute to the market growth over the coming years.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain vaccine contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Spain vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account